Supervisory Board

Friedrich v. Bohlen, PhD, Chairman

is managing director and co-founder of dievini GmbH & Co. KG, advisors in health sciences. Dievini manages the biotech investments of SAP co-founder Dietmar Hopp...

is managing director and co-founder of dievini GmbH & Co. KG, advisors in health sciences. Dievini manages the biotech investments of SAP co-founder Dietmar Hopp and his family. Friedrich von Bohlen studied biochemistry and holds a PhD in neurobiology from ETH Zuerich. He has held positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG Chemie AG.In 1997, he founded LION bioscience AG (now Sygnis Pharma AG) where he served as CEO for seven years. Since 2004, he has been chairman of the supervisory board of LION/Sygnis Pharma AG. He is also a member of the boards of Apogenix GmbH, Cosmo Pharmaceuticals SpA, Cytonet GmbH, immatics GmbH, Molecular Health GmbH, and Wilex AG.

Prof. Wolfgang Hartwig, PhD

is chairman of the Executive Board at LTS Lohmann Therapie-Systeme AG. Previously, he held various positions within Bayer Healthcare, including President and CEO of...

is chairman of the Executive Board at LTS Lohmann Therapie-Systeme AG. Previously, he held various positions within Bayer Healthcare, including President and CEO of the Diagnostics Division and head of Global Pharmaceuticals Research and Development.
He has served on public management and advisory boards including the Senatausschuss of the Helmholtz Association and the National Genome Research Initiative, and is at present a board member of several Biotech and Pharma companies in Europe. He has his own consulting firm and is Executive Consultant to the Bayer Holding Board. He is Honorary Professor at Westfaelische Wilhelms-University of Muenster.
Hartwig is also member of CureVac’s Scientific Advisory Board.

Baron Jean Stéphenne, MSc, MBA

is former Chairman of GSK Biologicals and President of GSK Biologicals. He began his career with SmithKline-Rit, where he became Chairman and Chief Executive Officer...

is former Chairman of GSK Biologicals and President of GSK Biologicals. He began his career with SmithKline-Rit, where he became Chairman and Chief Executive Officer. He served as the President of UWE (Union Wallonne des Entreprises) from 1997 to 2000. Baron Jean Stéphenne is chairman of  BESIX Group S.A./N.V. and TiGenix N.V. He serves as chairman or director in a few biotech companies.

Ralf Clemens, MD PhD

has been working in vaccine industry since 1988 in various senior scientific and business positions such as Head of GSK Biologicals' vaccine development and...

has been working in vaccine industry since 1988 in various senior scientific and business positions such as Head of GSK Biologicals' vaccine development and Latin American business, and thereafter leading the global vaccine development at Novartis. During these years Ralf developed and brought to licensure more than 25 different vaccines globally. Ralf graduated in medicine at the University of Mainz, Germany, and holds an executive business degree from the Wharton Business School, Philadelphia, US. He was member of the advisory board of the International Vaccine Institute in Seoul, Korea, and currently serves as external scientific advisor to the Bill & Melinda Gates Foundation, to the Institute of Infection and Global Health, University of Liverpool and to Aeras, a non-profit organization focusing in the development of vaccines against tuberculosis.

Mathias Hothum, PhD

is managing director of dievini GmbH & Co. KG, advisors in health sciences. Dievini manages the biotech Investments of SAP co-founder Dietmar Hopp...

is managing director of dievini GmbH & Co. KG, advisors in health sciences. Dievini manages the biotech investments of SAP co-founder Dietmar Hopp.
He received his Diploma degree in Economics from the University of Mannheim and his doctorate from the University of Magdeburg. For the past 20 years, he has gained experience as a health economist in the sectors healthcare, health services and life sciences. He specializes in pricing, reimbursement and in the evaluation of medium-sized companies as well as of publicly owned/market-listed companies. He is the owner and founder of HMM-Consulting. Furthermore, Mathias Hothum serves as a member of the boards of Apogenix GmbH, Cytonet GmbH, Joimax GmbH and Novaliq GmbH.

Chris Tanner, PhD

is Chief Financial Officer and Head of Investor Relations of Cassiopea since 2015. Since 2006 he has been a Board Member and CFO of Cosmo Pharmaceuticals SpA...

is Chief Financial Officer and Head of Investor Relations of Cassiopea since 2015. Since 2006 he has been a Board Member and CFO of Cosmo Pharmaceuticals SpA now SA. He is also a member of the board of directors or advisory board (Beirat) of DKSH AG (SIX: DKSH), Private Equity Holding AG (SIX: PEH), Qvanteq AG and Joimax GmbH. From 1998 to 2001 he was a partner of Dr. Ernst Mueller-Moehl and co-founder of the 20 Minutes group of newspapers, founded A&A Active Investor, a SIX listed investment company. From 1992 to 1998 he was the head of corporate finance & capital markets of UBS in Zurich and from 1976 to 1991 he had various functions in the Corporate Banking Department of UBS in Zurich, Madrid and Los Angeles. Dr. Tanner has a PhD in economics and diploma as an economist from the University of St. Gallen.
None of the companies where Chris Tanner has a management or board position major shareholder of has any business activities with CureVac.